Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin ® radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma - Wiseman, GA; White, CA; Sparks, RB (Crit Rev Oncol Hematol, 2001)
et al.